GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifewave Ltd (XTAE:LIFE) » Definitions » Inventories, Finished Goods

Switch to:

Lifewave (XTAE:LIFE) Inventories, Finished Goods : ₪0.00 Mil (As of . 20)

View and export this data going back to . Start your Free Trial

What is Lifewave Inventories, Finished Goods?

Lifewave Inventories, Finished Goods Historical Data

The historical data trend for Lifewave's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifewave Inventories, Finished Goods Chart

Lifewave Annual Data

Trend

Inventories, Finished Goods

Lifewave Quarterly Data

Inventories, Finished Goods

Lifewave Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Lifewave (XTAE:LIFE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifewave Ltd (XTAE:LIFE) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.life-wave.com

Lifewave (XTAE:LIFE) Headlines

From GuruFocus

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Systemic Sclerosis

By Marketwired • 06-22-2023

aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution

By sperokesalga sperokesalga • 03-21-2023

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

By Marketwired • 08-09-2023

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

By sperokesalga sperokesalga • 03-02-2023

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

By Value_Insider Value_Insider • 11-03-2022

aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application

By sperokesalga sperokesalga • 03-01-2023

aTyr Pharma Announces Pricing of Public Offering of Common Stock

By sperokesalga sperokesalga • 02-09-2023

aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference

By sperokesalga sperokesalga • 05-22-2023

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

By sperokesalga sperokesalga • 06-20-2023

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

By sperokesalga sperokesalga • 05-09-2023

Home About Jobs Site Map Term of Use Privacy Policy Mobile App Referral Program Partner Program FAQ Contact Us 中文 All-In-One Screener
Stock List Guru List Insider List Insider Trade Economic Indicators Industry Data DCF Calculator Discussion Board Plans Excel Add-In Google Sheets Add-on
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.